Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
A Multi-center, Open-label, Randomized, Controlled Study to Evaluate the Effectiveness of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD
The aim of this study is to evaluate the effectiveness of Yong Chong Cao capsule on outcomes in patients with mild to severe Chronic Obstructive Pulmonary Disease (COPD).
The aim of this study is to compare the effectiveness of two treatments for mild to severe
COPD patients: one, Yong Chong Cao capsule treatment and conventional medicine based on 2017
Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment
Guidelines; the other, Bailing capsule treatment and conventional medicine.
COPD, with high prevalence, morbidity, mortality and economic burdens, affects millions
worldwide. Although many therapies exist and are being developed to relieve symptoms and
reduce mortality in COPD, most have only been studied in placebo-controlled efficacy studies
in highly selected populations. There are few clinical trials to compare therapeutic
alternatives in real world. Furthermore, some randomized controlled trials on Yong Chong Cao
capsule, one therapeutic type of Cordyceps sinensis in traditional Chinese medicine (TCM)
interventions, especially based on the syndrome of insufficiency of qi of the lung and kidney
patterns, have been the certain evidence for showing definite effect for COPD patients. In
addition, studies in real world populations of COPD that received different cordyceps
sinensis therapies that do have efficacy evidence was found wide variations in care delivery.
In short, there is a need to compare the effectiveness of two capsule in patients with mild
to severe COPD.
This is a multi-center, open-label, randomized, controlled study to evaluate the
effectiveness of Yong Chong Cao capsule for patients with mild to severe COPD compared with
Bailing capsule. Following a 14 day run-in period, approximately 240 subjects will be
randomly assigned to Yong Chong Cao capsule treatment group, Bailing capsule treatment group
for 24 weeks. After the 24 weeks treatment period, subjects in two treatments arms will
follow-up 24 weeks. The primary outcome measure is the frequency of exacerbations. The
secondary efficacy measures include FEV1, dyspnea (MMRC), exercise capacity(6MWD), quality of
life (CAT, SGRQ). Safety will be assessed through the collection of adverse events. There
will be a total of 4 study visits (baseline, the 12 and 24 weeks of the treatment, the 24
weeks of follow-up).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
| Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
| Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
| Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
| Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
| Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
| Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
| Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
| Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
| Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
| Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
| Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
| Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
| Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
| Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
| Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
| Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
| Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|